<DOC>
	<DOCNO>NCT00311428</DOCNO>
	<brief_summary>This phase IV protocol design evaluate safety , clinical tolerability immunogenicity 2005-2006 formulation three widely use conventional influenza vaccine child age 6 35 month</brief_summary>
	<brief_title>Safety Immunogenicity Three Commercially Available Influenza Vaccines Children Aged 6 &lt; 36 Months</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>child 6 month &lt; 36 month age , whose parent legal guardian give write informed consent prior study entry Any severe acute respiratory disease infection require systemic antibiotic antiviral therapy ongoing resolve within 30 day prior study start ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) Other serious disease : cancer , autoimmune disease ( include rheumatoid arthritis ) , diabetes mellitus , chronic pulmonary disease , acute progressive hepatic renal disease , surgery plan study period . Known suspect impairment/alteration immune function History hypersensitivity component study vaccine , egg product vaccine component , impairment/alteration immune function</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Children</keyword>
	<keyword>Vaccine</keyword>
</DOC>